The Career Developmental Program (CDP) will support early career breast cancer researchers, who have research concepts focused on the biology, prevention, diagnosis, and treatment of breast cancer. The purpose of the CDP is to help develop the careers of young investigators committed to breast cancer, and it is hoped that these funds will support the awardees? efforts to become independent researchers. The Breast SPORE will designate a minimum of $250,000 a year to the CDP, $75,000 from SPORE funds and at least $175,000 from institutional commitment. The CDP is focused on young investigators at a junior faculty level. More senior individuals who wish to change their research focus to breast cancer are encouraged to apply for the SPORE Developmental Research Program awards, not the CDP, unless they are eligible for the Special Minority Career Advancement Award. All applicants for the Career Development Awards will be required to have a faculty appointment at a DF/HCC institution participating in the SPORE;individuals in a post-doctoral fellowship program may apply if their Department Chair will guarantee a faculty appointment year should the applicant receives a CDP award. Applicants need to have a nominating letter from a faculty mentor and should detail the mentoring plan, which preferably should include a mentoring committee. Because of the need to identify and develop breast cancer researchers from minority backgrounds, we have prioritized recruitment of minorities to our CDP awards and have also created a special award exclusively for minority candidates. The annual Request for Applications will be announced by e-mail, posted throughout the DF/HCC institutions via message boards and featured on the shared DF/HCC and SPORE website. The announcement will describe the purpose of the award, provide instructions for applicants, and detail the review criteria. The requirements for mentors, review criteria and steps to monitor progress are described in this section. The CDP provided one or two-year awards for 14 faculty members in the last SPORE (2000-2010). All awardees are currently cancer researchers and most have chosen to focus their careers on breast cancer. We are confident that we can surpass this degree of success in this new SPORE application.
The Career Development Program awards will support research projects proposed by individuals who are junior faculty members (instructor or assistant professor) or about to join the faculty. The CDP will promote the careers of junior investigators who have significant potential to contribute to breast cancer research. Since progress in breast cancer research is largely dependent on developing the next generation of breast cancer translational researchers, these awards are of considerable importance to establish a career in breast cancer research. Additionally, these projects may spawn more mature research projects whose aims are the prevention, early diagnosis or treatment of breast cancer.
|Spangle, Jennifer M; Dreijerink, Koen M; Groner, Anna C et al. (2016) PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep 15:2692-704|
|Montaser-Kouhsari, Laleh; Knoblauch, Nicholas W; Oh, Eun-Yeong et al. (2016) Image-guided Coring for Large-scale Studies in Molecular Pathology. Appl Immunohistochem Mol Morphol 24:431-5|
|Morganella, Sandro; Alexandrov, Ludmil B; Glodzik, Dominik et al. (2016) The topography of mutational processes in breast cancer genomes. Nat Commun 7:11383|
|Cheng, H; Liu, P; Ohlson, C et al. (2016) PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 35:2961-70|
|Choi, Young Eun; Meghani, Khyati; Brault, Marie-Eve et al. (2016) Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 14:429-39|
|Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6|
|Wang, Q; Liu, P; Spangle, J M et al. (2016) PI3K-p110Î± mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 35:3607-12|
|Nik-Zainal, Serena; Davies, Helen; Staaf, Johan et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47-54|
|Smid, Marcel; RodrÃguez-GonzÃ¡lez, F GermÃ¡n; Sieuwerts, Anieta M et al. (2016) Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 7:12910|
|Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381|
Showing the most recent 10 out of 38 publications